Cargando…
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects
Tumor necrosis factor alpha (TNF) is capable of inducing regression of solid tumors. However, TNF released in response to Toll-like receptor 4 (TLR4) activation by bacterial lipopolysaccharide (LPS) is the key mediator of cytokine storm and septic shock that can cause severe tissue damage limiting a...
Autores principales: | Haderski, Gary J., Kandar, Bojidar M., Brackett, Craig M., Toshkov, Ilia M., Johnson, Christopher P., Paszkiewicz, Geraldine M., Natarajan, Venkatesh, Gleiberman, Anatoli S., Gudkov, Andrei V., Burdelya, Lyudmila G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004342/ https://www.ncbi.nlm.nih.gov/pubmed/32027657 http://dx.doi.org/10.1371/journal.pone.0227940 |
Ejemplares similares
-
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice
por: Kojouharov, Bojidar M., et al.
Publicado: (2014) -
Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9
por: Brackett, Craig M., et al.
Publicado: (2021) -
The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates
por: Krivokrysenko, Vadim I., et al.
Publicado: (2015) -
The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism
por: Yang, Hua, et al.
Publicado: (2015) -
A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
por: Mett, Vadim, et al.
Publicado: (2021)